Knight Therapeutics Company Profile (CVE:GUD)

About Knight Therapeutics

Knight Therapeutics logoKnight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company's product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: GUD
  • CUSIP:
Key Metrics:
  • Previous Close: $10.67
  • 50 Day Moving Average: $10.46
  • 200 Day Moving Average: $9.67
  • 52-Week Range: C$132,704,000.00 - C$7.20
  • Trailing P/E Ratio: 75.14
  • P/E Growth: 2777.00
  • Market Cap: $1.42B
  • Outstanding Shares: 132,704,000
Additional Links:

Analyst Ratings

Consensus Ratings for Knight Therapeutics (CVE:GUD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
Show:
DateFirmActionRatingPrice TargetDetails
3/6/2015MackieInitiated CoverageBuyView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Knight Therapeutics (CVE:GUD)
Current Year EPS Consensus Estimate: $0.13 EPS

Dividends

Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Knight Therapeutics (CVE:GUD)
DateHeadline
News IconStock Update: Technicals in View for Knight Therapeutics Inc (GUD.TO) - Midway Monitor (CVE:GUD)
midwaymonitor.com - February 23 at 5:33 PM
benzinga.com logoKnight Therapeutics Inc. Announces Board Change - Benzinga (CVE:GUD)
www.benzinga.com - February 23 at 5:33 PM
marketwired.com logoAlimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada (CVE:GUD)
www.marketwired.com - February 22 at 12:58 PM
News IconShares in Review: Watching the Levels for Knight Therapeutics Inc. (TSX:GUD) - Providence Standard (CVE:GUD)
providencestandard.com - February 18 at 12:19 PM
streetinsider.com logoKnight Therapeutics Acquires 6.2M Shares of Protalix BioTherapeutics (PLX) (CVE:GUD)
www.streetinsider.com - January 27 at 7:29 PM
finance.yahoo.com logoKnight Plants Small Seed Position In Protalix (CVE:GUD)
finance.yahoo.com - January 27 at 12:04 AM
News IconLooking at the Numbers for Knight Therapeutics Inc. (TSX:GUD) - Gilbert Daily (CVE:GUD)
gilbertdaily.com - January 23 at 10:59 PM
News IconKnight Therapeutics Inc Stock Is Crashing Now - FairHerald News - Fair Herald (CVE:GUD)
fairherald.com - January 17 at 3:35 PM
finance.yahoo.com logoKnight Disposes of Shares of Pediapharm Inc. (CVE:GUD)
finance.yahoo.com - January 13 at 11:46 PM
News IconMedicure Provides Apicore Secured Loan To Replace Knight Therapeutics Loan (CVE:GUD)
www.biospace.com - January 9 at 4:27 PM
finance.yahoo.com logoAPI Is Core to Knight's Successful Investment (CVE:GUD)
finance.yahoo.com - January 9 at 4:27 PM
finance.yahoo.com logoMedicure Provides Apicore Secured Loan to Replace Knight Loan (CVE:GUD)
finance.yahoo.com - January 9 at 4:27 PM
finance.yahoo.com logoThe Top 5 Buys of Canada's CI Can-Am Small Cap Fund (CVE:GUD)
finance.yahoo.com - December 16 at 11:08 PM
News IconChecking the Levels on Shares of Knight Therapeutics Inc. (TSX:GUD) - Stock Newsweek (CVE:GUD)
stocknewsweek.com - December 13 at 10:51 AM
News IconWatching the Dials on Shares of Knight Therapeutics Inc (GUD.TO) - Wall Street Confidential (CVE:GUD)
wsconfidential.com - December 13 at 10:51 AM
marketwired.com logoKnight Therapeutics Enters into Agreement for a $75 Million Bought Deal of Common Shares (CVE:GUD)
www.marketwired.com - December 6 at 10:41 AM
investing.com logoEndo International: Surviving Despite Collusion Charges (CVE:GUD)
www.investing.com - November 6 at 5:42 PM
reuters.com logoExclusive: Endo International considers sale of Paladin Labs to Knight Therapeutics: sources (CVE:GUD)
www.reuters.com - November 4 at 4:17 PM
News IconLatest Reports on B2Gold, Knight Therapeutics, Lundin Mining, and Turquoise Hill Resources (CVE:GUD)
news.investornetwork.com - September 21 at 9:34 AM
capitalcube.com logoETF’s with exposure to Knight Therapeutics, Inc. : September 13, 2016 (CVE:GUD)
www.capitalcube.com - September 14 at 9:35 AM
theglobeandmail.com logoIf $10,000 fell into your lap, what would you do? (CVE:GUD)
www.theglobeandmail.com - September 1 at 8:16 AM
News IconFormer Paladin Labs CFO Named President at Knight Therapeutics (CVE:GUD)
www.biospace.com - August 18 at 8:20 AM
finance.yahoo.com logoKnight Medison Relationship Continues to Pay Dividends (CVE:GUD)
finance.yahoo.com - August 15 at 10:16 AM
finanznachrichten.de logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX (CVE:GUD)
www.finanznachrichten.de - August 2 at 5:37 PM
marketwired.com logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX™ (CVE:GUD)
www.marketwired.com - August 2 at 5:37 PM
marketwired.com logo3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and Distribution Agreements With Knight Therapeutics Inc. (CVE:GUD)
www.marketwired.com - July 22 at 8:17 AM
marketwired.com logoKnight Acquires Minor Stake in Pediapharm (CVE:GUD)
www.marketwired.com - July 15 at 4:25 PM
finanznachrichten.de logoKNIGHT THERAPEUTICS INC (CVE:GUD)
www.finanznachrichten.de - May 26 at 12:31 PM
finance.yahoo.com logo3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into Advisory Agreement With Knight Therapeutics Inc. (CVE:GUD)
finance.yahoo.com - May 26 at 12:16 PM
finance.yahoo.com logoKnight Reports First Quarter 2016 Results (CVE:GUD)
finance.yahoo.com - May 10 at 6:00 AM
finance.yahoo.com logoKnight Blooms at Healthcare Investor Conference in Toronto (CVE:GUD)
finance.yahoo.com - April 25 at 8:00 AM
finance.yahoo.com logoKnight Receives NOD from Health Canada for ATryn(R) (CVE:GUD)
finance.yahoo.com - April 25 at 8:00 AM
finance.yahoo.com logoKnight Finds EMPAthetic Partner for Neuragen(R) in the Middle East (CVE:GUD)
finance.yahoo.com - April 25 at 8:00 AM
biz.yahoo.com logoQ4 2015 KNIGHT THERAPEUTICS Inc Earnings Release - Time Not Supplied (CVE:GUD)
biz.yahoo.com - March 24 at 7:07 AM
finance.yahoo.com logoKnight Reports Fourth Quarter and Year-Ended December 31, 2015 Results (CVE:GUD)
finance.yahoo.com - March 24 at 6:00 AM
finance.yahoo.com logoKnight Receives Dividend From Medison (CVE:GUD)
finance.yahoo.com - March 23 at 8:00 AM
finance.yahoo.com logoKnight Partner Profounda Inc. Launches Impavido in U.S. (CVE:GUD)
finance.yahoo.com - March 22 at 8:03 AM
finance.yahoo.com logoProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States (CVE:GUD)
finance.yahoo.com - March 22 at 7:59 AM
finance.yahoo.com logoKnight Obtains Impavido Worldwide Rights (CVE:GUD)
finance.yahoo.com - March 15 at 8:00 AM
finance.yahoo.com logoKnight Therapeutics Inc. (GUD.TO) (CVE:GUD)
finance.yahoo.com - January 16 at 2:29 PM
finance.yahoo.com logoCRH Makes GUD on Knight Secured Loan (CVE:GUD)
finance.yahoo.com - November 25 at 8:00 AM
finance.yahoo.com logoKnight to Present at the TD Securities Technology & Healthcare Conference in Toronto (CVE:GUD)
finance.yahoo.com - November 17 at 8:00 AM
finance.yahoo.com logoKnight Partner FOCUSed on Growth (CVE:GUD)
finance.yahoo.com - November 16 at 8:00 AM
finance.yahoo.com logoKnight Supports Operation Antibe (CVE:GUD)
finance.yahoo.com - November 16 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : November 11, 2015 (CVE:GUD)
www.capitalcube.com - November 11 at 9:37 AM
finance.yahoo.com logoKnight Reports Third Quarter Financial 2015 Results (CVE:GUD)
finance.yahoo.com - November 11 at 6:00 AM
finance.yahoo.com logoThe Knight Medison Relationship Already Paying Dividends (CVE:GUD)
finance.yahoo.com - November 2 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. – Value Analysis (TORONTO:GUD) : October 28, 2015 (CVE:GUD)
www.capitalcube.com - October 28 at 1:55 PM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : October 15, 2015 (CVE:GUD)
www.capitalcube.com - October 15 at 10:11 AM
finance.yahoo.com logoKnight Profounda U.S. Partner for Impavido (CVE:GUD)
finance.yahoo.com - September 28 at 8:00 AM

Social

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GUD."

How do I buy Knight Therapeutics stock?

Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Knight Therapeutics stock cost?

One share of Knight Therapeutics stock can currently be purchased for approximately C$10.67.

Knight Therapeutics (CVE:GUD) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Knight Therapeutics (CVE:GUD)

Earnings History Chart

Earnings by Quarter for Knight Therapeutics (CVE:GUD)

Dividend History Chart

Dividend Payments by Quarter for Knight Therapeutics (CVE:GUD)

Last Updated on 2/26/2017 by MarketBeat.com Staff